Related Experiment Video

Updated: Aug 7, 2026

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy
10:18

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy

Published on: February 3, 2017

Targeting cell death in dementia

Paul Francis1

  • 1Wolfson Centre for Age-related Disorders, King's College London, London, UK. paul.francis@kcl.ac.uk

Alzheimer Disease and Associated Disorders
|June 15, 2006
PubMed

Insights

Alzheimer disease (AD) and vascular dementia (VaD) both involve neuronal degeneration. Despite different triggers, common downstream cell death pathways offer targets for neuroprotective agents in both neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Pathology
  • Neurology

Background:

  • Neuronal degeneration is central to Alzheimer disease (AD) and vascular dementia (VaD).
  • AD pathogenesis involves beta-amyloid and neurofibrillary tangles (NFTs).
  • VaD results from ischemic events (hemorrhage, hypoperfusion) causing oxygen and glucose deprivation.

Purpose of the Study:

  • To compare the neurodegenerative pathways in AD and VaD.
  • To identify common downstream mechanisms of cell death.
  • To explore potential therapeutic targets for neuroprotection.

Main Methods:

  • Comparative analysis of neurodegenerative processes in AD and VaD.
  • Identification of shared molecular pathways mediating neuronal cell death.
  • Review of potential intervention points for neuroprotective strategies.

Main Results:

  • AD and VaD exhibit distinct initial triggers and vulnerable neuronal populations.
  • Significant overlap exists in the downstream pathways leading to cell death.
  • Common cytotoxic pathways present multiple targets for neuroprotective agents.

Conclusions:

  • Despite differing etiologies, AD and VaD share common neurodegenerative pathways.
  • Targeting these shared pathways offers a promising strategy for developing neuroprotective therapies.
  • Further research into these common mechanisms could lead to effective treatments for both conditions.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...